Home > Formulary : Adult > Chapters > 2. Cardiovascular System >
BNSSG Adult Joint Formulary
2.5 Heart Failure
Last edited: 24-10-2024
First line drugs |
Second line drugs |
Specialist drugs |
Secondary care drugs |
See BNSSG Primary Care Heart Failure Treatment Guidance, Practical Guidance on how to use Heart Failure medications, Traffic Light: How to monitor renal function and potassium rises in stable heart failure patients - guidelines available here
Angiotensin Receptor Neprilysin Inhibitor
Sacubitril / Valsartan (Entresto) (TLS Amber 1 month) (SCP Click here)
Aldosterone Antagonists
Specific indications:
Spironolactone (TLS Blue)
- Heart Failure
- Hypertension (Step 4)
- Oedema in liver cirrhosis
- Conn's Syndrome
Eplerenone (TLS Amber Specialist Recommended)
- In addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with NYHA class II (chronic) heart failure and left ventricular dysfunction (LEVF ≤30%)
Sodium Glucose Co-transporter 2 Inhibitors
See Endocrine System Guidelines page for the 'Advice on the use of SGLT-2 inhibitors in Type 2 Diabetes, Heart Failure and Chronic Kidney Disease' aide memoire
Dapagliflozin (TLS Amber Specialist Recommended)
Empagliflozin (TLS Amber Specialist Recommended)
Phosphodiesterase Type-3 Inhibitors
Enoximone (TLS Red)
Milrinone (TLS Red)
Calcium Sensitiser
Levosimendan (TLS Red)
- under advice of consultant intensivist only
Selective Sinus Node If Inhibitors
- NICE TA267 Ivabradine for treating chronic heart failure
Other
Vericiguat (TLS Red)
- For the treatment of symptomatic chronic heart failure with reduced ejection fraction who are stabilised after a recent decompensation event requiring IV therapy. This treatment is reserved for patients who are on optimised standard therapy with a recent decompensation who have exhausted all other options under the care of the secondary care cardiology team
2.5.2 Cardiomyopathy
Obstructive Hypertrophic Cardiomyopathy
Mavacamten (TLS Red)
- NICE TA913 Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Transthyretin Amyloidosis Cardiomyopathy
Tafamidis (TLS Red)
- NICE TA984 Tafamidis for treating transthyretin amyloidosis with cardiomyopathy
Contact Us
Got a question or comment about the Joint Formulary?
Please use the email address below to contact us and we will endeavour to respond within 2 working days.